2.5 mg/ml semaglutide 5mg semaglutide 5mg ml 2ml vial

GLP-1 receptor agonists are licensed in the UK for type 2 diabetes and weight management, including semaglutide, dulaglutide, and liraglutide These medications reduce HbA1c by approximately 1.01.5 percentage points and improve both fasting and post-meal glucose levels Weight loss associated with GLP-1 therapy can lead to secondary improvements in insulin resistance, particularly through reduction of visceral fat Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhoea, which typically diminish over several weeks NICE recommends continuation only if patients achieve at least 1.0 percentage point HbA1c reduction within six months of treatment initiation Patients with diabetic retinopathy require close monitoring, and GLP-1 medications should be discontinued at least two months before planned pregnancy Table of Contents What Are GLP-1 Receptor Agonists and How Do They Work

Who Can Take GLP-1 Medications

Eli Lilly has also released competing GLP-1 drugs in the form of Mounjaro (tirzepatide), approved for diabetes treatment in 2022, and a weight loss version of the drug was approved by the FDA last year, which is marketed under the brand name Zepbound

In this context, precise evaluation and correct staging of fibrosis acquire a central role in monitoring MASLD progression, to identify patients with advanced or clinically significant fibrosis (stage 2) in a timely manner 6

However, in the context of weight loss injection use, maintaining a lower threshold for medical review is prudent given the potential for rare but serious complications